



## **Ripasudil free base**

**Catalog No: tcsc3402** 

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 223645-67-8
<b>Formula:</b> $C_{15}^{H}_{18}^{FN}_{3}^{O}_{2}^{S}$
Pathway: TGF-beta/Smad;Stem Cell/Wnt;Cell Cycle/DNA Damage
Target: ROCK;ROCK;
Purity / Grade: >98%
Solubility: 10 mM in DMSO
Alternative Names: K-115 (free base)





## **Observed Molecular Weight:**

323.39

## **Product Description**

Ripasudil free base (K-115 free base) is a specific inhibitor of **ROCK**, with **IC**<sub>50</sub>s of 19 and 51 nM for **ROCK2** and **ROCK1**, respectively.

IC50 & Target: IC50: 19 nM (ROCK2), 51 nM (ROCK1)<sup>[1]</sup>

In Vitro: Ripasudil (K-115) is a potent inhibitor of ROCK, with IC $_{50}$ s of 19 and 51 nM for ROCK2 and ROCK1, respectively. Ripasudil also shows less potent inhibitory activities against CaMKII $\alpha$ , PKAC $\alpha$  and PKC, with IC $_{50}$ s of 370 nM, 2.1  $\mu$ M and 27  $\mu$ M, respectively [1]. Ripasudil (K-115; 1, 10  $\mu$ M) induces cytoskeletal changes, including retraction and cell rounding and reduced actin bundles of cultured trabecular meshwork (TM) cells. Ripasudil (5  $\mu$ M) sifnificantly reduces transendothelial electrical resistance (TEER), and increases FITC-dextran permeability in Schlemm's canal endothelial (SCE) cell monolayers [2].

In Vivo: Ripasudil (K-115) reduces intraocular pressure (IOP) in a concentration-dependent manner at concentrations between 0.1% and 0.4% in monkey eyes and 0.0625% to 0.5% in rabbit eyes, respectively<sup>[1]</sup>. Ripasudil (K-115; 1 mg/kg, p.o. daily) shows a neuroprotective effect on retinal ganglion cells (RGCs) after nerve crush (NC). Ripasudil also inhibits the oxidative stress induced by axonal injury in mice. Ripasudil suppresses the time-dependent production of ROS in RGCs after NC injury<sup>[3]</sup>.

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!